Company | Ecolab Inc. |
Ticker | ECL (NYSE) |
Reporting Period | Q2 2026 (quarter ended June 30, 2026) |
Earnings Date | July 28, 2026 — 1:00 PM ET |
Prepared | July 27, 2026 |
Sector ETF (Chart) | XLI (Industrial Select Sector SPDR) |
Key Takeaway: The setup is modestly constructive — consensus has drifted only marginally since the Q1 print, the bar is achievable, and management already raised the Q2 EPS growth floor to 9–12% at the June 2 William Blair conference; the biggest swing factor is whether the energy surcharge fully offsets commodity cost inflation in-quarter, unlocking the H2 acceleration narrative.
Heading into the Q2 2026 print, the consensus bar is moderate and well-telegraphed: adjusted diluted EPS of ~$2.08 on revenue of ~$4.37 billion, implying roughly 10% EPS growth year-over-year — squarely within the 9–12% Q2 guidance range management raised at the William Blair Growth Stock Conference on June 2, 2026, more than halfway through the quarter. Management’s tone has shifted from cautious (Q2 framed as a “transition quarter” on April 28) to confident (low end of Q2 EPS growth guidance raised from 7% to 9%), citing strong execution on the April 1 energy surcharge and continued business momentum. Estimate revisions have been essentially flat since the Q1 print — Q2 EPS consensus moved from $2.078 to $2.080 — suggesting the street has largely accepted management’s framing and is not pricing in meaningful upside or downside. The stock has recovered from its post-Q1 dip (closed at $267 on earnings day, fell to ~$248 intra-period, and has since rebounded to ~$271), but multiple compression has been the dominant driver over the past 12 months (NTM EV/EBITDA contracted ~13% to 17.7x), meaning the stock needs an earnings catalyst to re-rate. The key wildcard is the magnitude of gross margin stabilization: if organic gross margins are flat-to-up ex-Ovivo in Q2 (as guided), it validates the H2 acceleration story and could drive a meaningful re-rating; if margins disappoint, the H2 guide of 6–7% organic sales growth and 14–15% EPS growth (ex-CoolIT) comes into question.
Key Takeaway: Consensus is a moderate, achievable bar — management has already guided to at least 4% organic sales growth and 9–12% EPS growth for Q2. Adjusted EPS is the primary swing factor; organic sales growth and operating margin are the supporting reads on whether the energy surcharge is working and whether H2 acceleration is credible.
KPI | Q1 2026 Actual | Q2 2025 Actual (Prior Year) | Q2 2026 Consensus Estimate | YoY Change | Guidance | Consensus vs. Guidance |
Net Sales ($B) | $4.066B | $4.025B | $4.371B | +8.5% YoY | Organic growth ≥40% | Above floor |
Adj. Diluted EPS ($) | $1.70 | $1.89 | $2.08 | +10.1% YoY | 9–12% growth (raised Jun 2) | ~+10% — at midpoint |
Organic Sales Growth (%) | 4.0% | 3.0% | ~4.8% | +180 bps YoY | ≥40% (floor) | Above floor |
Organic Price Impact (%) | 3.0% | 2.0% | ~4.4% | +240 bps YoY | Accelerating (surcharge) | Tracking guidance |
Organic Volume Impact (%) | 1.0% | 1.0% | ~0.7% | Flat YoY | Slight moderation expected | Tracking guidance |
Operating Margin — Adj. (%) | 16.7% | 18.3% | ~18.7% | +40 bps YoY | Stable organic gross margin ex-Ovivo | Tracking guidance |
Sources: Visible Alpha Consensus and Actuals Data (Net Sales, EPS — Diluted — Operating, Operating Margin — Operating, Organic Impact, Price Impact, Volume Impact). Q2 2026 consensus as of July 27, 2026. Guidance from ECL Q1 2026 Earnings Call (April 28, 2026) and William Blair Growth Stock Conference (June 2, 2026). Note: Net Sales guidance floor of “at least 4% organic growth” translates to an implied revenue floor; consensus of $4.371B is above that floor.
Quarter | Reported | Consensus | Surprise % | Result |
Q2 2024 | $1.68 | $1.670 | +0.6% | Beat |
Q3 2024 | $1.83 | $1.822 | +0.4% | Beat |
Q4 2024 | $1.81 | $1.795 | +0.8% | Beat |
Q1 2025 | $1.50 | $1.496 | +0.3% | Beat |
Q2 2025 | $1.89 | $1.904 | −0.7% | Miss |
Q3 2025 | $2.07 | $2.070 | 0.0% | In Line |
Q4 2025 | $2.08 | $2.071 | +0.4% | Beat |
Q1 2026 | $1.70 | $1.697 | +0.2% | Beat |
Quarter | Reported ($B) | Consensus ($B) | Surprise % | Result |
Q2 2024 | $3.986B | $4.030B | −1.1% | Miss |
Q3 2024 | $3.999B | $4.038B | −1.0% | Miss |
Q4 2024 | $4.005B | $4.006B | 0.0% | In Line |
Q1 2025 | $3.695B | $3.711B | −0.4% | Miss |
Q2 2025 | $4.025B | $4.034B | −0.2% | Miss |
Q3 2025 | $4.165B | $4.130B | +0.8% | Beat |
Q4 2025 | $4.196B | $4.185B | +0.3% | Beat |
Q1 2026 | $4.066B | $4.020B | +1.1% | Beat |
Pattern: ECL has beaten or matched adjusted EPS consensus in 7 of the last 8 quarters, with beats typically narrow (+0.2% to +0.8%), reflecting management’s practice of guiding conservatively and delivering at or slightly above the midpoint. Revenue beats have been less consistent — 4 misses in the prior 5 quarters before the recent Q3/Q4 2025 and Q1 2026 beats — suggesting the Ovivo consolidation and growth engine acceleration are now providing a more reliable top-line tailwind. Source: Visible Alpha Consensus and Actuals Data.
Key Takeaway: Management raised the Q2 EPS growth floor from 7% to 9% at the June 2 William Blair conference — the only formal guidance change since Q1 earnings. Tone has shifted from cautious (“transition quarter”) to confident, with the CFO citing strong surcharge execution and high visibility with more than half of Q2 complete at the time of the conference.
Metric | Initial Guidance (Q1 Earnings — Apr 28, 2026) | Revised Guidance | Current Consensus | Note |
Q2 2026 Adj. EPS Growth | 7% to 12% growth (below 12–15% FY range due to commodity headwind) | 9% to 12% growth | ~10.1% (consensus $2.08 vs. $1.89 prior year) | ↑ Raised at William Blair Conference Jun 2, 2026; CFO cited >50% of Q2 complete with strong surcharge execution and high visibility |
Q2 2026 Organic Sales Growth | Implied acceleration from Q1’s 4%; surcharge may “slightly” impact volumes | ≥40% (floor set at William Blair) | ~4.8% (consensus) | ↑ Floor raised at William Blair Jun 2, 2026; “minimum on sales is that 4%” — more confident tone on volume resilience |
Q2 2026 Organic Gross Margin | Stable organic gross margin expected as surcharge builds; reported gross margin lower due to Ovivo M&A impact | Stable organic gross margins ex-Ovivo; “gross margins to stabilize as we exit Q2” | ~18.7% adj. operating margin (consensus) | Unchanged in direction; William Blair added specificity that stabilization is expected at Q2 exit, not necessarily full-quarter average |
FY 2026 Adj. EPS Growth (ex-CoolIT) | 12% to 15% ($8.43–$8.63; midpoint $8.53) | Unchanged | $8.19 (consensus, includes CoolIT dilution impact) | Consensus below guidance midpoint due to ~$0.40 CoolIT H2 dilution ($0.20/quarter); underlying ex-CoolIT consensus tracks guidance |
H2 2026 Organic Sales Growth | 6% to 7% | Reaffirmed at William Blair; “organic sales growth accelerates to 6% to 7%” | ~5.1% FY consensus (implies H2 acceleration) | Unchanged; William Blair added that organic gross margin expands 75 bps in H2 and H2 adj. EPS growth reaches 14–15% ex-CoolIT |
CoolIT Acquisition EPS Impact (H2 2026) | ~$0.20/quarter dilution from financing & amortization; neutralizes in 2027 | Unchanged; CoolIT Q1 sales grew ~100% (vs. 30%+ expected) | Embedded in FY consensus | CoolIT tracking well ahead of plan; combined with Ovivo expected to add ~200 bps to top-line on pro forma annualized basis |
Key Takeaway: Q2 EPS estimates have been remarkably stable since the Q1 print (+0.1% drift), confirming the street has accepted management’s guidance range. FY 2026 EPS estimates have drifted down ~2.5% since the Q1 print, almost entirely explained by the CoolIT H2 dilution (~$0.40) being incorporated into consensus — not a deterioration in underlying business expectations.
KPI (Period) | Estimate ~5 Days Post Q1 Earnings (May 5, 2026) | Current Consensus (Jul 27, 2026) | Estimate Δ (%) | Initial Guidance (Q1 Earnings Call) | Current Guidance | Guidance Δ | Consensus vs. Guidance (%) |
Adj. EPS — Q2 2026 | $2.078 | $2.080 | +0.1% | 7–12% growth ($1.89 base → $2.02–$2.12) | 9–12% growth ($2.06–$2.12; raised Jun 2) | Floor raised +200 bps | At midpoint of raised range |
Net Sales — Q2 2026 | $4.372B | $4.371B | 0.0% | ≥40% organic growth (floor) | ≥40% organic growth (reaffirmed Jun 2) | Unchanged | Above floor |
Adj. EPS — FY 2026 | $8.399 | $8.186 | −2.5% | $8.43–$8.63 ex-CoolIT (12–15% growth) | Unchanged ex-CoolIT; CoolIT dilution ~$0.40 in H2 | Unchanged underlying | ~$0.34 below guidance midpoint ex-CoolIT; gap = CoolIT dilution |
Net Sales — FY 2026 | $17.651B | $17.807B | +0.9% | Organic growth 5–7% (H2 acceleration to 6–7%) | Unchanged; Ovivo/CoolIT add inorganic revenue | Unchanged | Tracking guidance; slight upward drift from M&A consolidation |
The ~2.5% decline in FY 2026 EPS consensus since the Q1 print is almost entirely mechanical — the street incorporated the ~$0.40 CoolIT H2 dilution (financing costs + amortization) that management disclosed on April 28. Underlying ex-CoolIT EPS trajectory is unchanged and tracking the 12–15% guidance range. Revenue estimates have drifted slightly higher (+0.9% for FY), reflecting Ovivo and CoolIT inorganic contributions. Source: Visible Alpha Consensus and Actuals Data.
Key Takeaway: ECL has underperformed XLI since the Q1 print (+1.7% vs. +7.2% for XLI and +3.9% for SPY), with the gap driven almost entirely by multiple compression rather than estimate cuts — NTM EV/EBITDA contracted from ~18.5x to ~17.7x over the past month, suggesting the market is waiting for proof of H2 acceleration before re-rating.
ECL closed at $266.96 on April 28 (Q1 earnings day), dipped to a trough of ~$245.73 by May 19 as the market digested the Q2 transition quarter framing and energy surcharge uncertainty, then recovered sharply through June and early July (peak ~$283.72 on July 6) before pulling back to ~$271 ahead of the print. Over the full period since Q1 earnings, ECL is up approximately +1.7%, lagging XLI (+7.2%) and SPY (+3.9%). The underperformance is multiple-driven: NTM EV/EBITDA has compressed from ~18.5x to ~17.7x over the past month, and from ~20.1x to ~17.7x over six months. Earnings estimates have been essentially flat, confirming that the stock’s relative weakness reflects valuation de-rating, not fundamental deterioration. The June 2 William Blair conference (energy surcharge raised guidance) triggered a visible re-acceleration in the stock from ~$256 to ~$284 over the following three weeks, suggesting the market is highly sensitive to surcharge execution signals. Source: Stock Price Data (Yahoo Finance).
Indexed Performance Since Q1 Earnings (April 28, 2026 = 100)
Date | ECL (Indexed) | XLI (Indexed) | SPY (Indexed) |
Apr 28 (Q1 Earnings) | 100.0 | 100.0 | 100.0 |
May 19 (Trough) | 92.1 | 98.7 | 103.0 |
Jun 2 (William Blair ↑ guidance) | 96.0 | 101.9 | 106.7 |
Jul 6 (Peak) | 106.3 | 108.5 | 105.6 |
Jul 27 (Pre-Earnings) | 101.7 | 107.2 | 103.9 |
Note: Indexed to 100 at April 28, 2026 close. ECL: $266.96; XLI: $170.98; SPY: $711.69. Key event: William Blair Growth Stock Conference June 2, 2026 (Q2 EPS guidance floor raised to 9%). Source: Stock Price Data (Yahoo Finance).
Key Takeaway: The most important development since Q1 earnings is the June 2 mid-quarter guidance raise, which de-risked the Q2 print and shifted focus to H2 execution. The CoolIT acquisition tracking at ~100% growth (vs. 30%+ expected) is the most underappreciated positive catalyst.
Key Takeaway: Peer commentary from the last 60 days is constructive for ECL’s Q2 setup: RPM International’s July 22 earnings (reporting its fiscal Q4 ending May 31, 2026, with forward commentary on its fiscal Q1 starting June 1) confirm continued strength in data centers, infrastructure, and industrial end markets, while flagging ongoing commodity inflation (5–8%) that validates ECL’s surcharge rationale. Note: Only commentary about ECL’s current reporting quarter (Q2 2026, ending June 30) or post-ECL Q1 earnings (after April 28, 2026) is included below. Prior-quarter peer results without forward commentary are excluded.
Screening criteria applied: Included only if (1) reported or commented after April 28, 2026 (post-ECL Q1 earnings), AND (2) commentary addresses conditions during or after calendar Q2 2026 (April–June 2026) or provides a forward outlook relevant to ECL’s end markets. Excluded: any peer commentary solely about that peer’s own prior-quarter results with no forward read-through.
RPM’s fiscal Q4 ended May 31, 2026; its forward commentary covers fiscal Q1 FY2027 (June–August 2026) and full-year FY2027, which directly overlaps with ECL’s Q2 and H2 2026 reporting periods. This is the most relevant peer read-through available.
While not a peer, ECL’s own mid-quarter commentary at William Blair is the most direct current-quarter read-through available and is included here for completeness as it post-dates Q1 earnings and addresses Q2 conditions directly.
Peers Not Included (Screening Rationale):
Key Takeaway: The insider signal is modestly constructive — two independent directors made open-market purchases in May–June (including a 7,750-share buy by Director Michel Doukeris), and the EVP of Global Supply Chain also bought 1,000 shares. The one open-market sale (Co-COO Darrell Brown, 10,000 shares) is notable in size but appears discretionary with no 10b5-1 plan flag.
Name | Title | Transaction Type | Shares | Date | Note |
Michel D. Doukeris | Director | Open Market Buy | 7,750 shares | Jun 10, 2026 | Largest director buy in the period; discretionary, no 10b5-1 plan; post-purchase holding: 8,326 shares |
Benjamin M. Clark | EVP — Global Supply Chain | Open Market Buy | 1,000 shares | Jun 11, 2026 | Discretionary buy by senior operating executive; no 10b5-1 plan; post-purchase holding: 1,083 shares |
Darrell R. Brown | Co-COO — Global Markets | Open Market Sale | 10,000 shares | Jun 9, 2026 | Discretionary sale; no 10b5-1 plan flag; post-sale holding: 32,733 shares (still significant); largest single transaction in the period |
David MacLennan | Director | Open Market Buy | 1,000 shares | May 13, 2026 | Second purchase by MacLennan in the period; discretionary; no 10b5-1 plan |
David MacLennan | Director | Open Market Buy | 800 shares | May 4, 2026 | First purchase by MacLennan in the period; discretionary; no 10b5-1 plan; total May purchases: 1,800 shares |
Summary: 4 open-market buys vs. 1 open-market sale since Q1 earnings. The cluster of director and senior executive purchases in May–June (at prices ranging from ~$248–$265) is a modestly positive signal, particularly the 7,750-share buy by Director Doukeris. The Co-COO sale of 10,000 shares is the only notable disposition; while discretionary (no 10b5-1 plan), Brown retains a substantial 32,733-share position. Net insider activity leans constructive. Source: Insider Transaction Data (SEC Form 4 Filings).